Overview
ELVN market data
Price History
ELVN price chart
Valuation & Profitability
No Valuation Data Yet
Alpha Vantage and Twelve Data both returned no valuation metrics for ELVN. Check back after the next daily valuation refresh — this symbol may be new, delisted, or temporarily unavailable from both providers.
Company news
Goldman Sachs Maintains Buy on Enliven Therapeutics, Raises Price Target to $67Benzinga · Jul 21, 2026, 12:40 PM
Stifel Maintains Buy on Enliven Therapeutics, Raises Price Target to $80Benzinga · Jul 1, 2026, 2:10 PM
Jones Trading Maintains Buy on Enliven Therapeutics, Raises Price Target to $70Benzinga · Jun 29, 2026, 3:40 PM
Medical Hedge Fund Sells 281,000 Shares of Enliven Theapeutics. Is it Time to Sell ELVN?The Motley Fool · Jun 24, 2026, 8:15 PM
8-K filing — Enliven Therapeutics, Inc. (ELVN)SEC EDGAR · Jun 12, 2026, 8:55 PM
Crude Oil Edges Higher; Driven Brands Posts Upbeat EarningsBenzinga · Jun 11, 2026, 3:44 PM
Stitch Fix, Intel, KLA And Other Big Stocks Moving Higher On ThursdayBenzinga · Jun 11, 2026, 2:10 PM
Enliven Therapeutics shares are trading higher after the company announced efficacy Phase 1 data for ELVN-001 in patients with chronic myeloid leukemia.Benzinga · Jun 11, 2026, 12:59 PM
Enliven Therapeutics Presents Data From The Phase 1 Enable Clinical Trial Evaluating ELVN-001 In Patients With Previously Treated Chronic Myeloid Leukemia; Notes Encouraging Efficacy Data By 24 WeeksBenzinga · Jun 11, 2026, 12:57 PM
This Grand Canyon Education Analyst Begins Coverage On A Bullish Note; Here Are Top 4 Initiations For TuesdayBenzinga · Jun 9, 2026, 11:10 AM